Discovery of a New and Selective HPK1 PROTAC for Enhancing Tumor Immunotherapy through Eliminating GLK Degradation
Mingfei Wu(Zhejiang University), Xiaowu Dong(Second Affiliated Hospital of Zhejiang University), Zheyuan Shen(Second Affiliated Hospital of Zhejiang University), Hengyuan Yu(Zhejiang University), Yiquan Wu(Zhejiang University), Nengming Lin(Westlake University), Wen-Tao Wang(Pharmaceutical Biotechnology (Czechia)), Jinxin Che(Pharmaceutical Biotechnology (Czechia)), Yong Chen(Pharmaceutical Biotechnology (Czechia)), Wenhai Huang(Hangzhou Medical College), Liuzhi Hu(Pharmaceutical Biotechnology (Czechia)), Tengfei Xu(China Agricultural University), Liteng Shen(Zhejiang Lab), Yuyuan Jin(Hangzhou Medical College), Xinfei Mao(Pharmaceutical Biotechnology (Czechia)), Bo Zhang(Hangzhou First People's Hospital), Shenxin Zeng(Hangzhou Medical College)
Cited by 6
Related Papers
ADCdb: the database of antibody–drug conjugates
|Nucleic Acids Research|2023|69
Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials
|PLoS ONE|2015|53
TransFoxMol: predicting molecular property with focused attention
|Briefings in Bioinformatics|2023|40
Rational Identification of Novel Antibody‐Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors
|Advanced Science|2024|34
N-Glycosylation on Asn50 of SND1 Is Required for Glioma U87 Cell Proliferation and Metastasis
|Journal of Immunology Research|2022|30